UK: Are Pharma R&D Returns Turning A Corner?

Last Updated: 22 December 2014
Article by Karen Young

Most Read Contributor in UK, August 2017

This week we launched our latest annual report on ' Measuring the return from pharmaceutical innovation' . Since 2010, we have been measuring the projected returns that the leading 12 life science companies are likely to deliver from the drugs they are developing in their late stage pipelines.

Despite an overall decline in R&D returns, from 10.1% in 2010 to 5.5% in 2014, our analysis shows that R&D returns may actually be turning a corner. This year, we estimate late stage pipelines returns for the cohort of companies to be 5.5%, representing an uplift from 5.1% in 2013. The most successful of the 12 companies in our analysis had an estimated R&D return of 11.7 per cent in 2014; the lowest R&D return for an individual company was estimated to be -0.7 per cent.

Over the last five years, the 12 companies have launched, in total, 143 products with projected, total lifetime revenues of $955 billion. Over the same period their R&D divisions have progressed 236 assets into their late stage pipelines, with projected, total lifetime revenues of $1,171 billion. This is no mean feat considering the continuing market hurdles they face including; ongoing austerity measures, increasing complexity of regulatory scrutiny and the scientific uncertainty in being able to address unmet need successfully.

Many of the companies in our cohort are negotiating these hurdles successfully and are continuing to populate their late stage pipelines with promising new compounds and bring new medical innovation to patients. However, our analysis reveals that challenges remain;

  • the cost of bringing an asset to market, including accounting for failures, has risen for the fifth consecutive year to $1,401 million
  • late stage terminations continue to cost the industry dear - across our cohort, for every $5 that has been launched, $2 has been lost to failure.

This year's findings indicate that the quality of assets in late stage development is improving. For the first time since 2010 the average forecast revenues of an individual asset have increased, regaining most of the ground lost since 2012, and the average forecast peak sales per asset have also recovered slightly, by $5 million since 2013.

The dynamics behind the uplift in R&D returns are complex with wide variations at the individual company level. This year, our analysis focussed on identifying characteristics of outperformance; what is it that sets apart those companies that are delivering higher than average returns? We found that size matters, as does therapy area focus and that assets acquired from external sources of innovation (for example via acquisition, co-development/joint-venture or licensing) have higher projected peak sales compared with assets developed internally.

Company size matters - our analysis reveals that the larger the company, by revenue or R&D spend, the greater the cost to develop each asset and the lower the returns. In addition, companies that pursue a large, broad portfolio of assets, without rigorous portfolio management and discipline, add significant cost without delivering adequate returns. Legacy investment burdens on larger R&D organisations may be one explanation. Furthermore, the sheer size, complexity and bureaucracy prevalent within some larger life sciences companies may be overshadowing the benefits of scale.

A focus on four or fewer therapy areas delivers better returns - our results show that those companies focusing on four or fewer therapy areas are forecast to deliver better returns from their late stage portfolios. A strong therapy area focus appears to provide companies with an in-depth knowledge of disease biology and a comprehensive disease management-based view, instead of a product-based view. Deep therapy area expertise also drives more effective commercial conversations with payers when negotiating price, reimbursement and market access.

Externally-sourced assets have higher, projected peak sales - three quarters of the companies in the cohort generate the majority (on average 58 per cent) of their forecast late stage pipeline revenues from intellectual property that is acquired externally. Our analysis also shows that forecast revenues from externally sourced assets, on average, are six per cent higher than assets which are self-originated. For those drugs with orphan or breakthrough status, the difference is significantly higher; 20 per cent higher for drugs with breakthrough status designation and an impressive 54 per cent higher for those with orphan drug status. These results highlight the importance of innovation strategies founded on collaboration, networking and asset acquisitions. The ability to engage in and subsequently manage strategic alliances effectively is a critical success factor in life sciences R&D.

The life sciences R&D ecosystem is undergoing a transformation that has forced the industry's biggest players to reinvent how they access, foster and commercialise innovation. Our findings indicate that some of the top 12 companies are further through their reinvention than others and, as a result, are delivering leading returns. Innovation strategies founded on collaboration, networking and asset acquisitions continue to grow in importance and impact; indeed, the ability to effectively engage in and subsequently manage strategic alliances is a critical success factor in life sciences R&D. What is clear, is that the ability to collaborate across the industry and with all stakeholders remains the imperative if returns are to continue to improve. Companies need to consider if they have invested in capabilities that make them 'collaboration ready', including the talent, processes, infrastructure and data required to collaborate effectively for the long term without eroding the value acquired.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.